NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE (Macrobid) Nursing Considerations

What is the generic name?

NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE

What is the Trade Name for NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE?

Macrobid

What are the Indications for NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE?

• INDICATIONS AND USAGE Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus . Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES ). Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized.

References: https://open.fda.gov/